Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
Minh Nguyen(Ignyta (United States)), Andrew D. Simmons(Clovis Oncology (United States)), Mark Armanini(Ignyta (United States)), Mary Haak‐Frendscho(Ignyta (United States)), Dongxia Gao(Baylor College of Medicine), Junichi Kato(Hiroshima University), Karen Gelmon(BC Cancer Agency), Rinat Yerushalmi(Rabin Medical Center), Kathleen Elias(Ignyta (United States)), Toshiyuki Mori(Takeda (Japan)), Shuichi Miyakawa(Toyota Motor Corporation (Switzerland)), Toshimitsu Arai(Takeda (Japan)), Gregory M. Landes(Molecular Oncology (United States)), Samuel Leung(BC Cancer Agency)
Cited by 26
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
|Journal of Clinical Oncology|2010|800
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
|Journal of Clinical Oncology|2014|795
Analysis of human transcriptomes
|Nature Genetics|1999|789
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676